These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30214153)

  • 1. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
    Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
    Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
    Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
    PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
    Beha N; Harder M; Ring S; Kontermann RE; Müller D
    Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.
    Xu H; Buhtoiarov IN; Guo H; Cheung NV
    Oncoimmunology; 2021 Mar; 10(1):1893500. PubMed ID: 33763293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
    Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
    J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
    Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
    Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
    Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
    Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.
    Mikkelsen K; Harwood SL; Compte M; Merino N; Mølgaard K; Lykkemark S; Alvarez-Mendez A; Blanco FJ; Álvarez-Vallina L
    Front Immunol; 2019; 10():1791. PubMed ID: 31417564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.